Table 4.
CMR finding before and after SARS-CoV-2 infection.
| Parameter | Before SARS-CoV-2 n = 18 | After SARS-CoV-2 n = 18 |
p |
|---|---|---|---|
| LV EDVi, mL/m2 | 118 ± 19 | 119 ± 19 | 0.493 |
| LV ESVi, mL/m2 | 51 ± 13 | 53 ± 11 | 0.069 |
| LV SVi, mL/m2 | 67 ± 9 | 66 ± 9 | 0.516 |
| LV EF, % | 57 ± 5 | 56 ± 4 | 0.081 |
| RV EDVi, mL/m2 | 117 ± 17 | 116 ± 17 | 0.494 |
| RV ESVi, mL/m2 | 55 ± 21 | 51 ± 10 | 0.333 |
| RV SVi, mL/m2 | 66 ± 9 | 65 ± 10 | 0.648 |
| RV EF, (%) | 56 ± 4 | 56 ± 4 | 0.957 |
| T1 Mapping Blood, ms | 1438 ± 73 | 1466 ± 98 | 0.26 |
| T1 Mapping Myo, ms | 935 ± 29 | 939 ± 48 | 0.746 |
| T2 Mapping Myo, ms | 51 ± 3 | 48 ± 2 | 0.099 |
| RV insertion point LGE, n (%) | NA | 2 (11) | NA |
EDVi: end diastolic volume index; ESVi: end systolic volume index; EF: ejection fraction; LGE: late gadolinium enhancement, LV: left ventricle; LV mass/i: left ventricular mass index; myo: myocardium; NA: not applicable; RV: right ventricle; SVi: stroke volume index.